My Library

University LibraryCatalogue

     
Limit search to items available for borrowing or consultation
Record 2 of 2
Result Page: Previous Next
Can't find that book? Try BONUS+
 
Look for full text

Search Discovery

Search CARM Centre Catalogue

Search Trove

Add record to RefWorks

Book Cover
E-RESOURCE

Title Evolution of translational omics : lessons learned and the path forward / Christine M. Micheel, Sharyl J. Nass, Gilbert S. Omenn, editors ; Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine of the National Academies.

Published Washington, D.C. : National Academies Press, [2012]

Copies

Location Call No. Status
 UniM INTERNET resource    AVAILABLE
Physical description 1 online resource (1 PDF file (xv, 338 pages) : illustrations
Series NCBI BookShelf
Notes Title from PDF title page.
Bibliography Includes bibliographical references.
Contents Introduction -- Omics-based clinical discovery: science, technology and applications -- Best practices for omics-based test validation prior to use for patient management decisions in a clinical trial setting -- Evaluation of omics-based tests for clinical utility and use -- Responsible parties -- Lessons from the case studies.
Summary Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.
Notes This study was supported by Contract Nos. HHSN261200900003C (National Cancer Institute); HHSF223201010692P and HHSF22301018T (Food and Drug Administration); and 200-2011-38807 and 200-2005-13434 (Centers for Disease Control and Prevention). This study was also supported by the U.S. Department of Veterans Affairs, the American Society for Clinical Pathology, and the College of American Pathologists. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.
Other author Micheel, Christine, editor.
Nass, Sharyl J., editor.
Omenn, Gilbert S., editor.
Institute of Medicine (U.S.). Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, sponsoring body.
National Library of Medicine issuing body.
Subject Genomics -- Technology.
Genomics -- Data processing.
Genetic translation -- Technology.
Biomolecules -- Analysis.
Biomolecules -- Data processing.
Bioinformatics -- Technology.
Data mining -- Analysis.
Biotechnology.
Electronic books.
ISBN 9780309224192 (electronic bk.)
0309224195 (electronic bk.)
9780309224185
0309224187
1283636409
9781283636407
6613948861
9786613948861
Standard Number 9786613948861